Table 2.

Performance of PCR to detect Aspergillus fumigatus in serum, determination of galactomannan index in serum and mycologic examination of respiratory samples for the diagnosis of invasive aspergillosis in 60 patients treated for proven/probable invasive aspergillosis according to extended EORTC/MSG criteria with the addition of PCR in the mycologic criteria

Method	Neutrophil status	Group	No. of samples with result		Sensitivity	Specificity	Positive predictive value	Negative predictive value	pb
			Positive	Negative
Galactomannan	All patients	IAa	40	20	66.7	87.7	27	97.5
		Non-IA	108	773
	Neutropenic	IA	19	9	67.8	83.9	22	97.5	0.93	Compared to nonneutropenic
		Non-IA	67	350					<0.005	Compared to nonneutropenic
	Nonneutropenic	IA	21	11	65.6	91.2	33.9	97.5
		Non-IA	41	423
Mycologic examination	All patients	IA	32	14	69.6	NA	NA	NA
	Neutropenic		8	9	47
	Nonneutropenic		24	5	82.7
PCR	All patients	IA	43	17	71.7	98.8	79.6	98
		Non-IA	11	870
	Neutropenic	IA	23	5	82.1	98.1	74.2	98.8	0.09	Compared to nonneutropenic
		Non-IA	8	409					0.09	Compared to nonneutropenic
	Nonneutropenic	IA	20	12	62.5	99.4	87	97.5
		Non-IA	3	461

EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycosis Study Group; IA, invasive aspergillosis; NA, not available.

^aCriteria used for classification of IA were those defined jointly by the EORTC/MSG consensus and published in 2008 with additionally inclusion of PCR as a mycologic criteria and minor modifications for host factors (e.g. inclusion of alcoholic liver cirrhosis).

^bAs calculated by chi-square test between neutropenic and nonneutropenic patients.